Local non-viral gene delivery of apoptin delays the onset of paresis in an experimental model of intramedullary spinal cord tumor

Spinal Cord

Volumn 52, Issue 1, 2014, Pages 3-8

  Pennant, W A ^a   An, S ^b   Gwak, S J ^a   Choi, S ^b   Banh, D T ^a   Nguyen, A B L ^a   Song, H Y ^a   Ha, Y ^a   Park, J S ^b  

^a Yonsei University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

Author keywords

apoptin; gene delivery; intramedullary spinal cord tumor; non viral; PAM RG4

Indexed keywords

APOPTIN; EOSIN; HEMATOXYLIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; EXPERIMENTAL MODEL; GENE; GLIOMA; HINDLIMB; HISTOPATHOLOGY; INTRAMEDULLARY SPINAL CORD TUMOR; LOCAL NON VIRAL GENE DELIVERY; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; PARESIS; PRIORITY JOURNAL; RAT; SCORING SYSTEM; SPINAL CORD; SPINAL CORD TUMOR; STAINING; STRENGTH; TUMOR GROWTH; VIRUS CARRIER;

ANIMALS; CAPSID PROTEINS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; MALE; PARESIS; RATS; RATS, SPRAGUE-DAWLEY; SPINAL CORD NEOPLASMS;

EID: 84891748297     PISSN: 13624393     EISSN: 14765624     Source Type: Journal    
DOI: 10.1038/sc.2013.106     Document Type: Article

References (48)

1. Adams H, Avendano J, Raza SM, Gokaslan ZL, Jallo GI, Quinones-Hinojosa A. Prognostic factors and survival in primary malignant astrocytomas of the spinal cord: a population-based analysis from 1973 to 2007. Spine 2012; 37: E727-E735.
2. Parsa AT, Lee J, Parney IF, Weinstein P, McCormick PC, Ames C. Spinal cord and intradural-extraparenchymal spinal tumors: current best care practices and strategies. J Neuro-Oncol 2004; 69: 291-318.
3. Townsend N, Handler M, Fleitz J, Foreman N. Intramedullary spinal cord astrocytomas in children. Pediatr Blood Cancer 2004; 43: 629-632.
4. Van Goethem JWM, van den Hauwe L, Ozsarlak O, De Schepper AMA, Parizel PM. Spinal tumors. Eur J Radiol 2004; 50: 159-176.
5. Bowers DC, Weprin BE. Intramedullary spinal cord tumors. Curr Treat Options Neurol 2003; 5: 207-212.
6. Sandler HM, Papadopoulos SM, Thornton AF, Ross DA. Spinal cord astrocytomas: results of therapy. Neurosurgery 1992; 30: 490-493.
7. Steinbok P, Cochrane DD, Poskitt K. Intramedullary spinal cord tumors in children. Neurosurg Clin N Am 1992; 3: 14.
8. McCormick PC, Stein BM. Intramedullary tumors in adults. Neurosurg Clin N Am 1990; 1: 609-630.
9. Minehan KJ, Shaw EG, Scheithauer BW, Davis DL, Onofrio BM. Spinal cord astrocytoma: pathological and treatment considerations. J Neurosurg 1995; 83: 590-595.
10. Osullivan C, Jenkin RD, Doherty MA, Hoffman HJ, Greenberg ML. Spinal cord tumors in children: long term results of combined surgical and radiation treatment. J Neurosurg 1994; 81: 507-512.
11. Schick U, Marquardt G, Lorenz R. Recurrence of benign spinal neoplasms. Neurosurg Rev 2001; 24: 20-25.
12. Shirato H, Kamada T, Hida K, Koyanagi I, Iwasaki Y, Miyasaka K et al. The role of radiotherapy in the management of spinal cord glioma. Int J Radiat Oncol 1995; 33: 323-328.
13. Balmaceda C. Chemotherapy for intramedullary spinal cord tumors. J Neuro-Oncol 2000; 47: 293-307.
14. Doireau V, Grill J, Zerah M, Lellouch-Tubiana A, Couanet D, Chastagner P et al. Chemotherapy for unresectable and recurrent intramedullary glial tumors in children. Br J Cancer 1999; 81: 835-840.
15. Fouladi M, Hunt DL, Pollack IF, Dueckers G, Burger PC, Becker LE et al. Outcome of children with centrally reviewed low-grade gliomas treated with chemotherapy with or without radiotherapy on Childrens Cancer Group high-grade glioma study CCG-945. Cancer Am Cancer Soc 2003; 98: 1243-1252.
16. Henson JW, Thornton AF, Louis DN. Spinal cord astrocytoma: response to PCV chemotherapy. Neurology 2000; 54: 518-520.
17. Mora J, Cruz O, Gala S, Navarro R. Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. Neuro-Oncology 2007; 9: 39-46.
18. Colak A, Goodman JC, Chen SH, Woo SLC, Grossman RG, Shine HD. Adenovirusmediated gene-therapy for experimental spinal cord tumors: tumoricidal efficacy and functional outcome. Brain Res 1995; 691: 76-82.
19. Won YW, Kim KM, An SS, Lee M, Ha Y, Kim YH. Suicide gene therapy using reducible poly (oligo-D-arginine) for the treatment of spinal cord tumors. Biomaterials 2011; 32: 9766-9775.
20. Noteborn MHM, Deboer GF, Vanroozelaar DJ, Karreman C, Kranenburg O, Vos JG et al. Characterization of cloned chicken anemia virus DNA that contains all elements for the infectious replication cycle. J Virol 1991; 65: 3131-3139.
21. Noteborn MHM, Todd D, Verschueren CAJ, HWFM Degauw, Curran WL, Veldkamp S et al. A single chicken anemia virus protein induces apoptosis. J Virol 1994; 68: 346-351.
22. Danen-vanOorschot AAAM, Fischer DF, Grimbergen JM, Klein B, Zhuang SM, Falkenburg JHF et al. Apoptin induces apoptosis in human transformed and malignant cells but not in normal cells. Proc Natl Acad Sci USA 1997; 94: 5843-5847.
23. Noteborn MHM, Danen-van Oorschot AAAM, Van der Eb AJ. The apoptin gene of chicken anemia virus in the induction of apoptosis in human tumorigenic cells and in gene therapy of cancer. In: Boulikas T (ed.). Gene Therapy Mol Biol 1998; 1: 399-406.
24. Lian H, Jin NY, Li X, Mi ZQ, Zhang JM, Sun LL et al. Induction of an effective antitumor immune response and tumor regression by combined administration of IL-18 and apoptin. Cancer Immunol Immun 2007; 56: 181-192.
25. Olijslagers SJ, Zhang YH, Backendorf C, Noteborn MHM. Additive cytotoxic effect of apoptin and chemotherapeutic agents paclitaxel and etoposide on human tumour cells. Basic Clin Pharmacol 2007; 100: 127-131.
26. Oorschot AAAMD, Zhang Y, Erkeland SJ, Fischer DF, van der Eb AJ, Noteborn MHM. The effect of Bcl-2 on Apoptin in normal vs transformed human cells. Leukemia 1999; 13: S75-S77.
27. Zhuang SM, Shvarts A, Vanormondt H, Jochemsen AG, Vandereb AJ, Noteborn MHM. Apoptin, a protein derived from chicken anemia virus, induces p53-independent apoptosis in human osteosarcoma cells. Cancer Res 1995; 55: 486-489.
28. Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006; 5: 10-19.
29. Maddika S, Booy EP, Johar D, Gibson SB, Ghavami S, Los M. Cancer-specific toxicity of apoptin is independent of death receptors but involves the loss of mitochondrial membrane potential and the release of mitochondrial cell-death mediators by a Nur77- dependent pathway. J Cell Sci 2005; 118: 4485-4493.
30. Lin BZ, Kolluri SK, Lin F, Liu W, Han YH, Cao XH et al. Conversion of Bcl-2 from protector to killer by interaction with nuclear orphan receptor Nur77/TR3. Cell 2004; 116: 527-540.
31. Nam HY, Nam K, Hahn HJ, Kim BH, Lim HJ, Kim HJ et al. Biodegradable PAMAM ester for enhanced transfection efficiency with low cytotoxicity. Biomaterials 2009; 30: 665-673.
32. Caplan J, Pradilla G, Hdeib A, Tyler BM, Legnani FG, Bagley CA et al. A novel model of intramedullary spinal cord tumors in rats: functional progression and histopathological characterization. Neurosurgery 2006; 59: 193-199.
33. Basso DM, Beattie MS, Bresnahan JC. Graded histological and locomotor outcomes after spinal cord contusion using the NYU weight-drop device versus transection. Exp Neurol 1996; 139: 244-256.
34. An S, Nam K, Choi S, Bai CZ, Lee Y, Park J. Nonviral gene therapy in vivo with PAM-RG4/apoptin as a potential brain tumor therapeutic. Int J Nanomed 2013; 8: 821-834.
35. Pennant WA, Sciubba DM, Noggle JC, Tyler BM, Tamargo RJ, Jallo GI. Microsurgical removal of intramedullary spinal cord gliomas in a rat spinal cord decreases onset to paresis, an animal model for intramedullary tumor treatment. Child Nerv Syst 2008; 24: 901-907.
36. Hayashi K, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M et al. A color-coded orthotopic nude-mouse treatment model of brain-metastatic paralyzing spinal cord cancer that induces angiogenesis and neurogenesis. Cell Proliferat 2009; 42: 75-82.
37. Tyler BM, Hdeib A, Caplan J, Legnani FG, Fowers KD, Brem H et al. Delayed onset of paresis in rats with experimental intramedullary spinal cord gliosarcoma following intratumoral administration of the paclitaxel delivery system OncoGel Laboratory investigation. J Neurosurg Spine 2012; 16: 8.
38. Fischer D, Li YX, Ahlemeyer B, Krieglstein J, Kissel T. In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 2003; 24: 1121-1131.
39. Choi JS, Nam K, Park J, Kim JB, Lee JK, Park J. Enhanced transfection efficiency of PAMAM dendrimer by surface modification with L-arginine. J Control Release 2004; 99: 445-456.
40. Kim JB, Choi JS, Nam K, Lee M, Park JS, Lee JK. Enhanced transfection of primary cortical cultures using arginine-grafted PAMAM dendrimer, PAMAM-Arg. J Control Release 2006; 114: 110-117.
41. Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999; 6: 882-892.
42. Xiao L, Yan L, Zhongmei W, Chang L, Huijun L, Mingyao T et al. Potent anti-tumor effects of a dual specific oncolytic adenovirus expressing apoptin in vitro and in vivo. Mol Cancer 2010; 9: 10.
43. Zhang KJ, Qian J, Wang SB, Yang Y. Targeting gene-viro-therapy with AFP driving apoptin gene shows potent antitumor effect in hepatocarcinoma. J Biomed Sci 2012; 19: 20.
44. Pan YF, Fang LR, Fan HY, Luo R, Zhao Q, Chen HC et al. Antitumor effects of a recombinant pseudotype baculovirus expressing Apoptin in vitro and in vivo. Int J Cancer 2010; 126: 2741-2751.
45. Ma JL, Han SX, Zhao J, Zhang D, Wang L, Li YD et al. Systemic delivery of lentivirusmediated secretable TAT-apoptin eradicates hepatocellular carcinoma xenografts in nude mice. Int J Oncol 2012; 41: 1013-1020.
46. Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004; 23: 1153-1165.
47. Maddika S, Wiechec E, Ande SR, Poon IK, Fischer U, Wesselborg S et al. Interaction with PI3-kinase contributes to the cytotoxic activity of apoptin. Oncogene 2008; 27: 3060-3065.
48. Jin HL, Pennant WA, Lee MH, An SS, Kim HA, Liu ML et al. Neural stem cells modified by a hypoxia-inducible VEGF gene expression system improve cell viability under hypoxic conditions and spinal cord injury. Spine 2011; 36: 857-864.